Cullinan Oncology Inc
NASDAQ:CGEM
Income Statement
Earnings Waterfall
Cullinan Oncology Inc
Income Statement
Cullinan Oncology Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
19
N/A
|
19
N/A
|
19
N/A
|
19
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(60)
|
(58)
|
(75)
|
(82)
|
(87)
|
(102)
|
(121)
|
(132)
|
(130)
|
115
|
(163)
|
(178)
|
(191)
|
(171)
|
(184)
|
(187)
|
(197)
|
(209)
|
(235)
|
(241)
|
|
| Selling, General & Administrative |
(17)
|
(19)
|
(23)
|
(28)
|
(29)
|
(32)
|
(36)
|
(41)
|
(38)
|
(41)
|
(42)
|
(43)
|
(42)
|
(44)
|
(48)
|
(50)
|
(54)
|
(55)
|
(56)
|
(56)
|
|
| Research & Development |
(43)
|
(39)
|
(51)
|
(54)
|
(58)
|
(70)
|
(85)
|
(92)
|
(92)
|
(120)
|
(120)
|
(135)
|
(148)
|
(127)
|
(136)
|
(137)
|
(143)
|
(154)
|
(178)
|
(185)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
275
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(60)
N/A
|
(39)
+36%
|
(56)
-45%
|
(63)
-12%
|
(68)
-8%
|
(102)
-50%
|
(121)
-18%
|
(132)
-9%
|
(130)
+2%
|
115
N/A
|
(163)
N/A
|
(178)
-9%
|
(191)
-7%
|
(171)
+10%
|
(184)
-7%
|
(187)
-2%
|
(197)
-5%
|
(209)
-6%
|
(235)
-12%
|
(241)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
7
|
11
|
16
|
19
|
22
|
23
|
26
|
28
|
30
|
31
|
28
|
25
|
|
| Non-Reccuring Items |
0
|
(1)
|
0
|
0
|
0
|
0
|
275
|
275
|
275
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(59)
N/A
|
(39)
+34%
|
(55)
-42%
|
(62)
-13%
|
(67)
-8%
|
(101)
-50%
|
155
N/A
|
146
-6%
|
151
+4%
|
126
-17%
|
(147)
N/A
|
(158)
-8%
|
(169)
-7%
|
(148)
+12%
|
(158)
-7%
|
(160)
-1%
|
(167)
-5%
|
(179)
-7%
|
(207)
-16%
|
(217)
-5%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
20
|
(47)
|
(44)
|
(42)
|
(62)
|
4
|
2
|
14
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(59)
|
(39)
|
(55)
|
(62)
|
(67)
|
(82)
|
109
|
102
|
109
|
64
|
(142)
|
(157)
|
(155)
|
(134)
|
(144)
|
(145)
|
(168)
|
(179)
|
(207)
|
(217)
|
|
| Income to Minority Interest |
8
|
1
|
2
|
1
|
2
|
4
|
4
|
3
|
2
|
1
|
1
|
0
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(52)
N/A
|
(38)
+26%
|
(54)
-41%
|
(61)
-14%
|
(66)
-7%
|
(78)
-18%
|
113
N/A
|
105
-7%
|
111
+5%
|
65
-41%
|
(142)
N/A
|
(156)
-10%
|
(153)
+2%
|
(132)
+14%
|
(142)
-7%
|
(144)
-1%
|
(167)
-17%
|
(179)
-7%
|
(207)
-16%
|
(217)
-5%
|
|
| EPS (Diluted) |
-1.25
N/A
|
-0.92
+26%
|
-1.24
-35%
|
-1.41
-14%
|
-1.52
-8%
|
-1.74
-14%
|
2.43
N/A
|
2.31
-5%
|
2.38
+3%
|
1.6
-33%
|
-3.54
N/A
|
-3.65
-3%
|
-3.69
-1%
|
-3.07
+17%
|
-2.58
+16%
|
-2.46
+5%
|
-3.11
-26%
|
-3.03
+3%
|
-3.52
-16%
|
-3.68
-5%
|
|